VIATRIS INC. Other Comprehensive Income (Loss), Net of Tax
VIATRIS INC. (VTRS) reported Other Comprehensive Income (Loss), Net of Tax of -$25.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- VIATRIS INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$25.00M, a 112.11% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$92.80M, a 127.13% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $6.20M.
- VIATRIS INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$48.80M, a 116.89% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), net of tax for fiscal 2025 was $505.90M.
- VIATRIS INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$465.50M, a 3473.19% decline from fiscal 2023.
- VIATRIS INC. other comprehensive income (loss), net of tax for fiscal 2023 was $13.80M.
- VIATRIS INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$1.02B.
| Period end | Other Comprehensive Income (Loss), Net of Tax 1 month | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 4 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 7 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 11 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$25.00M 10-Q · filed 2026-08-06 | -$117.80M 10-Q · filed 2026-08-06 | -$111.60M derived: sum of 3 quarters · filed 2026-08-06 | -$160.40M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$92.80M 10-Q · filed 2026-05-07 | -$86.60M derived: sum of 2 quarters · filed 2026-05-07 | -$135.40M derived: sum of 3 quarters · filed 2026-05-07 | $71.10M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$42.60M derived: sum of 2 quarters · filed 2026-02-26 | $163.90M derived: sum of 3 quarters · filed 2026-08-06 | $505.90M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$48.80M 10-Q · filed 2025-11-06 | $157.70M derived: sum of 2 quarters · filed 2026-08-06 | $499.70M 10-Q · filed 2025-11-06 | -$26.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $206.50M 10-Q · filed 2026-08-06 | $548.50M 10-Q · filed 2026-08-06 | $21.90M derived: sum of 3 quarters · filed 2026-08-06 | $310.80M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $342.00M 10-Q · filed 2026-05-07 | -$184.60M derived: sum of 2 quarters · filed 2026-05-07 | $104.30M derived: sum of 3 quarters · filed 2026-05-07 | $70.10M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$526.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$237.70M derived: sum of 2 quarters · filed 2026-02-26 | -$271.90M derived: sum of 3 quarters · filed 2026-02-26 | -$465.50M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $288.90M 10-Q · filed 2025-11-06 | $254.70M derived: sum of 2 quarters · filed 2025-11-06 | $61.10M 10-Q · filed 2025-11-06 | $522.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$34.20M 10-Q · filed 2025-08-07 | -$227.80M 10-Q · filed 2025-08-07 | $233.30M derived: sum of 3 quarters · filed 2026-02-26 | $30.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | -$193.60M 10-Q · filed 2025-05-08 | $267.50M derived: sum of 2 quarters · filed 2026-02-26 | $64.60M derived: sum of 3 quarters · filed 2026-02-26 | -$176.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $461.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $258.20M derived: sum of 2 quarters · filed 2026-02-26 | $17.20M derived: sum of 3 quarters · filed 2026-02-26 | $13.80M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$202.90M 10-Q · filed 2024-11-07 | -$443.90M derived: sum of 2 quarters · filed 2024-11-07 | -$447.30M 10-Q · filed 2024-11-07 | $550.60M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | -$241.00M 10-Q · filed 2024-08-08 | -$244.40M 10-Q · filed 2024-08-08 | $753.50M derived: sum of 3 quarters · filed 2025-02-27 | -$106.40M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$3.40M 10-Q · filed 2024-05-09 | $994.50M derived: sum of 2 quarters · filed 2025-02-27 | $134.60M derived: sum of 3 quarters · filed 2025-02-27 | -$703.60M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $997.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $138.00M derived: sum of 2 quarters · filed 2025-02-27 | -$700.20M derived: sum of 3 quarters · filed 2025-02-27 | -$1.02B 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$859.90M 10-Q · filed 2023-11-08 | -$1.70B derived: sum of 2 quarters · filed 2023-11-08 | -$2.01B 10-Q · filed 2023-11-08 | -$2.29B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | -$838.20M 10-Q · filed 2023-08-07 | -$1.15B 10-Q · filed 2023-08-07 | -$1.43B derived: sum of 3 quarters · filed 2024-02-28 | -$1.69B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | -$316.70M 10-Q · filed 2023-05-08 | -$589.10M derived: sum of 2 quarters · filed 2024-02-28 | -$856.00M derived: sum of 3 quarters · filed 2024-02-28 | -$675.40M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | -$272.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$539.30M derived: sum of 2 quarters · filed 2024-02-28 | -$358.70M derived: sum of 3 quarters · filed 2024-02-28 | -$886.30M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | -$266.90M 10-Q · filed 2022-11-07 | -$86.30M derived: sum of 2 quarters · filed 2022-11-07 | -$613.90M 10-Q · filed 2022-11-07 | -$48.10M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $180.60M 10-Q · filed 2022-08-08 | -$347.00M 10-Q · filed 2022-08-08 | $218.80M derived: sum of 3 quarters · filed 2023-02-27 | $819.90M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | -$527.60M 10-Q · filed 2022-05-09 | $38.20M derived: sum of 2 quarters · filed 2023-02-27 | $639.30M derived: sum of 3 quarters · filed 2023-02-27 | |||||
| 2020-12-31 | $565.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.17B derived: sum of 2 quarters · filed 2023-02-27 | $939.20M 10-K · filed 2023-02-27 | |||||
| 2020-09-30 | $601.10M 10-Q · filed 2021-11-08 | $373.40M 10-Q · filed 2021-11-08 | ||||||
| 2020-09-27 | $0.00 10-Q · filed 2020-11-10 | $428.60M derived: sum of 2 quarters · filed 2021-08-09 | $0.00 10-Q · filed 2020-11-10 | |||||
| 2020-06-30 | $428.60M 10-Q · filed 2021-08-09 | -$227.70M 10-Q · filed 2021-08-09 | ||||||
| 2020-06-28 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||||||
| 2020-03-31 | -$656.30M 10-Q · filed 2021-05-10 | |||||||
| 2020-03-29 | $0.00 10-Q · filed 2020-05-12 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2020-05-07 | -$352.30M 10-K · filed 2022-02-28 | ||||||
| 2019-09-29 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 | |||||||
| 2018-12-31 | -$1.07B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |